Investors had a good mind to plow money into Mind Medicine (NASDAQ: MNMD) stock on Tuesday. Shares of the psychedelic-focused biotech, which also goes by the name of MindMed, provided a nice high by ...

Recent discussions on X about Mind Medicine (MindMed) stock, listed as MNMD, have been buzzing with interest following news of growing political momentum for psychedelic therapies. Many users are ...

Back in 2024, on May 14, a caller brought up Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a biotech company focused on psychedelic treatments for mental health. Cramer said he was supportive back then, ...

Mind Medicine (NASDAQ: MNMD), a healthcare company that's looking to develop treatments based on psychedelic compounds, was something of a sleeper stock in May. Several positive developments pushed ...

Shares of Mind Medicine (NASDAQ:MNMD) rallied on Monday after Oppenheimer upgraded the psychedelic drug developer to Outperform, citing the potential of its lead candidate MM120, an optimized form of ...

Mind Medicine’s share price continues to be volatile and influenced by broad market sentiment towards the psychedelics sector. Clinical trials for MM120 are progressing well, with no sign of delays to ...

Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health ...

Late on Monday, Connecticut's House of Representatives approved a bill to decriminalize psilocybin, the psychoactive compound found in so-called "magic" mushrooms. The vote was narrow, with 74 of the ...

One state's House of Representatives just voted in favor of decriminalizing psilocybin. This is the compound the company is trying to develop into medicines. Late on Monday, Connecticut's House of ...